On September 22, 2025 Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reported the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress (Press release, Delcath Systems, SEP 22, 2025, View Source [SID1234656145]). Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath’s CHEMOSAT Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastatic uveal melanoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab in Metastatic Uveal Melanoma: a single center, open-label, randomized, phase 2 study (CHOPIN)
Session Title: Melanoma and other skin tumours
Session Date and Time: Saturday, October 18, 2025 3:20 p.m. CET / 9:20 a.m. EST
Abstract Number: LBA59
Presenter: Ellen Kapiteijn, MD
The poster will be available at View Source when the ESMO (Free ESMO Whitepaper) embargo is released on October 18, 2025.